Articles

Lilly cancer drug OK’d for new use

Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.

Read More

Minority suppliers diversifying into life sciences

The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under
way on a national scale.

Read More

With pharma famine looming, Lilly relying on snack-size deals

Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.

Read More

Dow may need to sell Indy’s Dow AgroSciences

Financially strapped Dow Chemical Co. acknowledges it may sell Indianapolis-based Dow AgroSciences LLC, the ag-chemicals-and-biotech
firm that’s one of the biggest jewels in the city’s life sciences crown.

Read More

Advanced energy next focus for economic development

The Central Indiana Corporate Partnership—the parent of the BioCrossroads, TechPoint and Conexus industry cluster initiatives—let it be known last month that there would be a fourth leg to its economic development stool: clean technology.

Read More